RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 20th, 2013 • Prosensa Holding B.V. • Pharmaceutical preparations • England
This RESEARCH, DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of October 6, 2009 (the “Effective Date”) by and between PROSENSA Holding BV, a company incorporated under the laws of the Netherlands and with registered number 28076693, whose offices are located at Wassenaarseweg 72, 2333 AL Leiden, The Netherlands (“PROSENSA”), and Glaxo Group Limited, a company incorporated under the laws of England and Wales with registered number 00305979, whose registered office is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). PROSENSA and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Amendment Agreement #1Amendment Agreement • May 20th, 2013 • Prosensa Holding B.V. • Pharmaceutical preparations
This Amendment Agreement #1 (the “Amendment”) is made effective July 1st, 2011 (the “Amendment Effective Date”) by and between PROSENSA Holding BV, a company incorporated under the laws of the Netherlands and with registered number 28076693, whose offices are located at J.H. Oortweg 21, 2333 CH Leiden, The Netherlands (“Prosensa”), and Glaxo Group Limited, a company incorporated under the laws of England and Wales with registered number 00305979, whose registered office is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). Prosensa and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties”. All capitalized terms that are used in this Amendment and not defined herein shall have the meanings ascribed to them in the Original Agreement. Except as specifically modified by or otherwise agreed to in this Amendment, the Parties hereto agree that all of the terms and conditions set forth in the Original Agreement remain in full
RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT IN RELATION TO The “Clinical development of the compounds Exon 44, Exon 45 and Exon 53 for RNA-based therapy to treat Duchenne Muscular Dystrophy” programme, led by Dr. Giles Campion, CMO & SVP...Development Collaboration Agreement • May 20th, 2013 • Prosensa Holding B.V. • Pharmaceutical preparations
This Research and Development Collaboration Agreement (the “Contract”) is entered into with effect as of January 1, 2010 (the “Effective Date”) by and between:
